Aspects physiopathologiques du rôle du microbiote intestinal et de l’inflammation dans les troubles de l’humeur, et leurs implications thérapeutiques

Description :

Study population: Patients in a current episode of MDD admitted at Hôtel-Dieu de France University Hospital, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-IV criteria, and not currently taking any antidepressant medication. • Necessary inclusion and exclusion and exclusion criteria will be applied. • Healthy individuals and controls will be recruited: A group of controls matched for number, age, gender, diet, sociodemographic characteristics, life circumstances. • Informed consent: Subjects will have a face-to-face meeting with the physician who will explain the study. If in agreement, the subject will be asked to sign and complete the consent form. • Double-blinded observational study • Relevant surveys for both controls and patients will be used to evaluate: eating habits using the Mediterranean diet questionnaire, sociodemographic characteristics, other comorbidities, medications (antidepressant and others), history of psychiatric treatment, GI disorders, BMI. • Metagenomics analysis will be performed on fecal samples, inflammatory state evaluation on blood samples, both for depressed and control patents • Effect of probiotic intake will be evaluated in probiotic vs placebo groups • In parallel, metagenomics analysis, inflammatory state evaluation and effect of probiotic intake will be performed on mice using the unpredictable chronic mild stress depressive model.